Randomized Comparison of Safety and Pharmacokinetics of Caspofungin, Liposomal Amphotericin B, and the Combination of Both in Allogeneic Hematopoietic Stem Cell Recipients
暂无分享,去创建一个
J. Gerss | C. Lanvers-Kaminsky | A. Groll | H. Ostermann | O. Cornely | C. Young | W. Heinz | H. Kolve | R. Schwerdtfeger | J. P. Vieira Pinheiro | Gudrun Wuerthwein | G. Silling | Sibylle Gammelin
[1] A. Groll,et al. Recent advances in antifungal prevention and treatment. , 2009, Seminars in hematology.
[2] B. Spellberg,et al. Recent advances in the management of mucormycosis: from bench to bedside. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[3] A. Vekhoff,et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[4] E. Bow. Invasive Fungal Infection in Haematopoietic Stem Cell Transplant Recipients: Epidemiology from the Transplant Physician’s Viewpoint , 2009, Mycopathologia.
[5] J. Perfect,et al. Antifungal Therapy for Invasive Fungal Diseases in Allogeneic Stem Cell Transplant Recipients: An Update , 2009, Mycopathologia.
[6] J. Wingard,et al. Combination antifungal therapy: From bench to bedside , 2008, Current infectious disease reports.
[7] R. Goldberg,et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[8] Patricia Muñoz,et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[9] L. Ostrosky-Zeichner. Combination antifungal therapy: a critical review of the evidence. , 2008, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[10] B. Spellberg,et al. Combination Echinocandin-Polyene Treatment of Murine Mucormycosis , 2008, Antimicrobial Agents and Chemotherapy.
[11] R. Betts,et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[12] K. Bartlett,et al. Assessing the antifungal activity, pharmacokinetics, and tissue distribution of amphotericin B following the administration of Abelcet and AmBisome in combination with caspofungin to rats infected with Aspergillus fumigatus. , 2007, Journal of pharmaceutical sciences.
[13] C. Heussel,et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[14] D. Pittet,et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial , 2007, The Lancet.
[15] J. Szer,et al. Caspofungin as salvage monotherapy for invasive aspergillosis in patients with haematological malignancies or following allogeneic stem cell transplantation: efficacy and concomitant cyclosporin A , 2007, Mycoses.
[16] J. Perfect,et al. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[17] J. Perfect,et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. , 2007, The New England journal of medicine.
[18] A. Glasmacher,et al. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis , 2006, Cancer.
[19] F. Barchiesi,et al. Caspofungin in Combination with Amphotericin B against Candida parapsilosis , 2006, Antimicrobial Agents and Chemotherapy.
[20] E. Sionov,et al. Efficacy of amphotericin B or amphotericin B-intralipid in combination with caspofungin against experimental aspergillosis. , 2006, The Journal of infection.
[21] A. Attarbaschi,et al. Treatment with caspofungin in immunocompromised paediatric patients: a multicentre survey. , 2006, The Journal of antimicrobial chemotherapy.
[22] D. Benjamin,et al. Safety and Pharmacokinetics of Intravenous Anidulafungin in Children with Neutropenia at High Risk for Invasive Fungal Infections , 2006, Antimicrobial Agents and Chemotherapy.
[23] D. Kontoyiannis,et al. Pharmacokinetics, Safety, and Efficacy of Posaconazole in Patients with Persistent Febrile Neutropenia or Refractory Invasive Fungal Infection , 2006, Antimicrobial Agents and Chemotherapy.
[24] J. Adler-Moore,et al. Treatment of Candida glabrata Infection in Immunosuppressed Mice by Using a Combination of Liposomal Amphotericin B with Caspofungin or Micafungin , 2005, Antimicrobial Agents and Chemotherapy.
[25] Rachana Parmar,et al. Comparative Efficacies of Conventional Amphotericin B, Liposomal Amphotericin B (AmBisome), Caspofungin, Micafungin, and Voriconazole Alone and in Combination against Experimental Murine Central Nervous System Aspergillosis , 2005, Antimicrobial Agents and Chemotherapy.
[26] A. Shad,et al. Pharmacokinetics, Safety, and Tolerability of Caspofungin in Children and Adolescents , 2005, Antimicrobial Agents and Chemotherapy.
[27] G. Verhoef,et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[28] A. Shad,et al. Safety, Tolerability, and Pharmacokinetics of Micafungin (FK463) in Febrile Neutropenic Pediatric Patients , 2005, Antimicrobial Agents and Chemotherapy.
[29] M. Rinaldi,et al. Caspofungin in Combination with Amphotericin B against Candida glabrata , 2005, Antimicrobial Agents and Chemotherapy.
[30] A. Elmaagacli,et al. Caspofungin as second-line therapy for fever of unknown origin or invasive fungal infection following allogeneic stem cell transplantation , 2005, Bone Marrow Transplantation.
[31] D. Denning,et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[32] Thomas J Walsh,et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. , 2004, The New England journal of medicine.
[33] G. Papanicolaou,et al. Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A , 2004, Transplant infectious disease : an official journal of the Transplantation Society.
[34] C. Solano,et al. Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections , 2004, Bone Marrow Transplantation.
[35] Russell E. Lewis,et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies , 2003, Cancer.
[36] L. Wheat. Combination therapy for aspergillosis: is it needed, and which combination? , 2003, The Journal of infectious diseases.
[37] M. Ghannoum,et al. Efficacy of caspofungin combined with amphotericin B against azole-resistant Candida albicans. , 2003, The Journal of antimicrobial chemotherapy.
[38] K. Sepkowitz,et al. Refractory Aspergillus pneumonia in patients with acute leukemia , 2003, Cancer.
[39] J. Perfect,et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. , 2002, The New England journal of medicine.
[40] A. Sterrett,et al. Single- and Multiple-Dose Pharmacokinetics of Caspofungin in Healthy Men , 2002, Antimicrobial Agents and Chemotherapy.
[41] T. Walsh,et al. Pharmacokinetics, Excretion, and Mass Balance of Liposomal Amphotericin B (AmBisome) and Amphotericin B Deoxycholate in Humans , 2002, Antimicrobial Agents and Chemotherapy.
[42] D. Kontoyiannis,et al. Rationale for Combination Antifungal Therapy , 2001, Pharmacotherapy.
[43] A. Groll,et al. Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections , 2001, Expert opinion on investigational drugs.
[44] G. Noel,et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. , 1999, The Journal of pediatrics.
[45] W. Wilson,et al. Safety, Tolerance, and Pharmacokinetics of a Small Unilamellar Liposomal Formulation of Amphotericin B (AmBisome) in Neutropenic Patients , 1998, Antimicrobial Agents and Chemotherapy.
[46] J. Smith,et al. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872) , 1997, Antimicrobial agents and chemotherapy.
[47] D. Denning,et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[48] R. Finberg,et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. , 1999, The New England journal of medicine.
[49] S. Piscitelli,et al. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. , 1998, Advances in pharmacology.
[50] Empiric antifungal therapy in febrile granulocytopenic patients. EORTC International Antimicrobial Therapy Cooperative Group. , 1989, The American journal of medicine.
[51] M Tubiana,et al. The European Organization for Research and Treatment of Cancer (EORTC). , 1988, International journal of radiation oncology, biology, physics.
[52] F. Witebsky,et al. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. , 1982, The American journal of medicine.